DR. REDDY'S LABORATORIES-ADR (RDY)
US2561352038 - ADR
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
Novo to face Wegovy rivalry in India as local versions loom
Novo Nordisk (NVO) faces scrutiny as Indian drugmakers develop their versions of its weight loss therapy Wegovy. Read more here.
Dr. Reddy’s Q3 & 9M FY24 Financial Results
Journey Medical submits NDA for DFD-29 for rosacea (NASDAQ:DERM)
Journey Medical (FBIO) said it has submitted a New Drug Application for its rosacea treatment DFD-29. The product is being developed with Dr. Reddy's (RDY). Read more here.
Dr. Reddy's acquires MenoLabs business from Amyris (NYSE:RDY)
Dr. Reddy's Laboratories has announced the acquisition of Amyris' women's health and dietary supplements portfolio.
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
Dr. Reddy's acquires 6.46% stake in Israeli biotech Edity Therapeutics (NYSE:RDY)
Dr. Reddy's Laboratories (RDY) has acquired a 6.46% stake in Edity Therapeutics, an Israeli biotech focused on using immune cells to deliver therapeutics proteins. Read more here.
AbbVie, Amgen cited in latest Medicare inflation penalties
The Biden administration identifies 48 Medicare Part B drugs subject to inflation penalties in Q1 2024. Read more here.
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
Dr Reddy's licenses Coya ALS candidate in exclusive deal (NASDAQ:COYA)
Coya Therapeutics and Dr. Reddy's Laboratories collaborate on drug for ALS, with Dr.
Dr. Reddy's flagged by FDA over quality issues (NYSE:RDY)
The U.S. FDA cites multiple manufacturing violations at one of production sites run by Dr. Reddy's Laboratories (RDY) in India. Read more here.
Dr. Reddy’s Q2 FY24 Financial Results
Dr. Reddy's GAAP EPS of $1.07, revenue of $828M beats by $11.97M
Dr. Reddy's (RDY) Q2 FY24 earnings report reveals a GAAP EPS of $1.07 and $828M revenue, beating expectations by $11.97M.
Oversold Conditions For Dr. Reddy's Laboratories
Dr. Reddy's launches generic version of Kombiglyze XR in US (NYSE:RDY)
Indian drugmaker Dr. Reddys Laboratories (RDY) said it has launched a generic equivalent of AstraZeneca's (AZN) diabetes medication Kombiglyze XR for the US market. Read more here.
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Dr. Reddy’s Q1 FY24 Financial Results
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Journey Medical stock rallies 20% on Phase 3 studies update (NASDAQ:DERM)
Journey Medical (DERM) stock rallied 20% in midday trading Monday following news that it expects to receive topline results the week of July 10 from two Phase 3 clinical trials.
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
The 3 Most Undervalued Value Stocks to Buy in June 2023
One positive aspect about broader market challenges is the rising opportunity in the best undervalued value stocks for June.
Notable Two Hundred Day Moving Average Cross - RDY
Relative Strength Alert For Dr. Reddy's Laboratories
(NYSE:RDY)
Dr. Reddy's press release (RDY): Q4 GAAP EPS of $0.70.Revenue of $766M (+6.8% Y/Y) beats by $8.32M.
Dr. Reddy’s Q4 & FY23 Financial Results
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
